arrow
M

Michael R. Savona

vanderbilt university medical center
H指数:53
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients With Higher-Risk Myelodysplastic Syndromes/Neoplasms: An analysis From the International Consortium for MDS (icMDS)

基于低甲基化制剂治疗的反应对高风险骨髓增生异常综合征/肿瘤患者生存结局的影响:考虑基线临床-分子风险和移植状态的国际骨髓增生异常综合征联盟(icMDS)分析

2026-08-280
PRE
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

治疗相关细胞减少症与低危骨髓增生异常综合征患者对imetelstat临床反应之间的关联

2026-04-070
OAAI
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

接受伊美替拉stat治疗低风险骨髓增生异常新生物患者的克隆性负荷调节

Leukemia
IF13.4
2026-01-120
OAAI
Clonal hematopoiesis activates procalcific pathways in macrophages and promotes aortic valve stenosis

克隆性造血激活巨噬细胞中的促钙化通路并促进主动脉瓣狭窄

2026-01-023
OA
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

前期疗法对依赖输血、ESA复发或难治/不适用LR-MDS患者中imetelstat临床活性的影响

2025-12-310
OAAI
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

低剂量阿糖胞苷和维奈克拉在不符合强化疗条件的急性髓系白血病患者中的风险分层

2025-11-240
OAAI
Decitabine-cedazuridine in patients with MDS and TP53 mutations

地西他滨-西达佐鲁定在伴TP53突变的患者中的研究

2025-11-140
OAAI
Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

低危骨髓增生异常综合征患者接受伊米替列stat治疗后的临床疗效与安全性:IMerge三期试验的子研究

2025-11-010
OAAI
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms

国际骨髓增生异常综合征/骨髓肿瘤工作组关于骨髓报告标准化的共识

2025-10-010
OA
IMPACT OF PRIOR TREATMENTS ON THE CLINICAL ACTIVITY OF IMETELSTAT IN PATIENTS WITH TRANFUSION-DEPENDENT (TD), ERYTHROPOIESIS-STIMULATING AGENT (ESA) RELAPSED/REFRACTORY/INELIGIBLE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS)

既往治疗对输血依赖性(TD)、促红细胞生成剂(ESA)复发/难治/不适用低危骨髓增生异常综合征(LR-MDS)患者中imetelstat临床活性的影响

2025-09-010
OAAI
INCORPORATING TET2 VARIANT ALLELE FREQUENCY ENHANCES PROGNOSTICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA: A MULTICENTER STUDY

纳入TET2变异等位基因频率可增强慢性粒单细胞白血病的预后评估:一项多中心研究

2025-09-010
PRE
Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

多发性骨髓瘤患者接受及未接受来那度胺维持治疗时克隆性造血的演变

Leukemia
IF13.4
2025-07-160
OAAI